F. Andrew Dorr, MD; Michael A. Friedman, MD
To the Editor: The recent editorial by Pritchard (1) summarized the sometimes contentious debate that followed the distribution of the National Cancer Institute's Clinical Alert in May 1988. The author focused on how many women must be treated for the benefit of a minority and at what cost. She asked whether disease-free survival represents a sufficient benefit or if, in this group of patients, the quality of life lost due to adjuvant therapy is such that improved disease-free survival is not worth its cost.
It was heartening to see the Clinical Alert referred to as a "temperate presentation of preliminary
Dorr FA, Friedman MA. Node-Negative Breast Cancer and the Clinical Alert. Ann Intern Med. ;111:622. doi: 10.7326/0003-4819-111-7-622
Download citation file:
Published: Ann Intern Med. 1989;111(7):622.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use